Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05904548 · ClinicalTrials.gov registry record · NA
Atrial Flutter Ablation in the iCMR
A NA study of Atrial Flutter Typical, sponsored by Imricor Medical Systems.
- Recruiting
- Registry status
- NA
- Development phase
- 91
- Enrollment target
- 6
- Study locations
NCT05904548: Recruiting NA study of Atrial Flutter Typical, sponsored by Imricor Medical Systems.
NCT05904548 is a NA study of Atrial Flutter Typical that is actively recruiting participants, run by Imricor Medical Systems. The registered enrollment target is 91 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05904548, a NA study of Atrial Flutter Typical, is actively recruiting participants, sponsored by Imricor Medical Systems.
- RECRUITING
- Registry status
- NA
- Development phase
- 91 participants
- Enrollment target
- 6
- Study locations
Study Summary
The VISABL-AFL clinical investigation is a prospective, single-arm, multi-center, interventional, Investigational Device Exemption (IDE) trial. The primary objectives of VISABL-AFL are to assess the safety and efficacy of radiofrequency (RF) ablation of type-I atrial flutter performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.
Primary Outcome
Confirmation of bidirectional conduction block of the CTI with the Vision-MR Ablation Catheter 2.0 and Osypka HAT 500 RF generator \& irrigation pump.
Conditions Studied
Interventions
- DEVICE RF Ablation
Study Locations (6)
Other
- l'institut Cardiologique Paris Sud (ICPS) - Massy
- Amsterdam University Medical Center (AUMC) - Amsterdam
- University Hospital of Vaud (CHUV) - Lausanne
Virginia
- University of Virginia (UVA) - Charlottesville
- Virginia Commonwealth University - Richmond
Maryland
- Johns Hopkins University (JHU) - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2024-06-20 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT05904548 shows while recruiting
NCT05904548 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Atrial Flutter Typical appearing as the primary indexed condition, and to 1 intervention - of which RF Ablation is the first listed.
NCT05904548 lists 6 locations in 3 states (Other, Virginia, Maryland).
Frequently Asked Questions
What is clinical trial NCT05904548 about?
NCT05904548 is a clinical study titled "Atrial Flutter Ablation in the iCMR". The VISABL-AFL clinical investigation is a prospective, single-arm, multi-center, interventional, Investigational Device Exemption (IDE) trial. The primary objectives of VISABL-AFL are to assess the safety and efficacy of radiofrequency (RF) ablation of type-I atrial flutter performed with the Visio...
What is the current status of trial NCT05904548?
This trial is currently recruiting. It is a NA study. The enrollment target is 91 participants. The study started on 2024-06-20. Estimated completion is 2026-12-31.
What conditions does trial NCT05904548 study?
This clinical trial studies the following conditions: Atrial Flutter Typical.
What interventions are being tested in trial NCT05904548?
The interventions under investigation include: RF Ablation (DEVICE).
Who is sponsoring clinical trial NCT05904548?
This trial is sponsored by Imricor Medical Systems, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05904548 being conducted?
This trial has 6 study locations across Maryland, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05904548's enrollment target sits among peer trials
91 939th of 2000 higher than 1,060 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI